vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease (AD) and diabetes,
announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP,
Clinical Development, and Carmen Valcarce, SVP, Chief Scientific
Officer, will participate in an analyst-led fireside chat at 4:00 p.m.
EST on Wednesday, December 2 at the Piper Jaffray 27th Annual Healthcare
Conference.
A live webcast can be accessed on the News
& Events section of the website. The webcast will be
archived for 30 days following the presentation on the company website
at www.vtvtherapeutics.com.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and Type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151124005098/en/
Copyright Business Wire 2015